Compare · BDX vs MDT
BDX vs MDT
Side-by-side comparison of Becton Dickinson and Company (BDX) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BDX focuses on Medical/Dental Instruments, while MDT focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus.
- MDT is the larger of the two at $109.98B, about 2.3x BDX ($48.79B).
- Over the past year, BDX is down 6.1% and MDT is down 6.0% - MDT leads by 0.1 points.
- MDT has been more active in the news (14 items in the past 4 weeks vs 11 for BDX).
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- Medtronic plc.
- Price
- $176.26-0.44%
- $85.86-0.03%
- Market cap
- $48.79B
- $109.98B
- 1M return
- +16.84%
- +4.19%
- 1Y return
- -6.07%
- -5.99%
- Industry
- Medical/Dental Instruments
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 11
- 14
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest BDX
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
- EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch
- BD Board Declares Dividend
- EVP, Chief Revenue Officer Feld Michael sold $11,785 worth of shares (75 units at $157.13) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 20,934 units (SEC Form 4)
- UBS initiated coverage on Becton Dickinson with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
Latest MDT
- Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias
- Chief Accounting Officer Blomquist Denise L. covered exercise/tax liability with 212 units of Ordinary Shares and was granted 2,337 units of Ordinary Shares, increasing direct ownership by 14% to 16,998 units (SEC Form 4)
- EVP & President, Neuroscience Thompson Kweli covered exercise/tax liability with 1,739 units of Ordinary Shares and was granted 6,923 units of Ordinary Shares, increasing direct ownership by 17% to 35,390 units (SEC Form 4)
- SVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 1,675 units of Ordinary Shares and was granted 5,769 units of Ordinary Shares, increasing direct ownership by 11% to 39,928 units (SEC Form 4)
- EVP, GC and Secretary Quinn Michelle was granted 6,346 units of Ordinary Shares, increasing direct ownership by 31% to 26,721 units (SEC Form 4)
- EVP & Chief Financial Officer Pieton Thierry was granted 11,537 units of Ordinary Shares, increasing direct ownership by 30% to 49,645 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael was granted 57,107 units of Ordinary Shares and covered exercise/tax liability with 3,356 units of Ordinary Shares, increasing direct ownership by 84% to 117,420 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 3,074 units of Ordinary Shares and was granted 9,230 units of Ordinary Shares, increasing direct ownership by 16% to 43,669 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey was granted 41,533 units of Ordinary Shares and covered exercise/tax liability with 15,810 units of Ordinary Shares, increasing direct ownership by 9% to 327,866 units (SEC Form 4)
- EVP, GC and Secretary Quinn Michelle covered exercise/tax liability with 2,069 units of Ordinary Shares, decreasing direct ownership by 9% to 20,375 units (SEC Form 4)